Phase 1 trial supports safety and mechanism of action of peptide immunotherapy for peanut allergy. Voskamp AL, Khosa S, Phan T, DeBerg HA, et al. Allergy 2023 Dec 19. doi: 10.1111/all.15966.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Voskamp AL, Khosa S, Phan T, DeBerg HA, et al. Phase 1 trial supports safety and mechanism of action of peptide immunotherapy for peanut allergy. Allergy 2023 Dec 19. doi: 10.1111/all.15966.
PMID: 38112286